Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications

被引:74
作者
Highland, Jaclyn N. [1 ,6 ]
Zanos, Panos [1 ,2 ,3 ]
Riggs, Lace M. [1 ,7 ,8 ]
Georgiou, Polymnia [1 ]
Clark, Sarah M. [1 ]
Morris, Patrick J. [9 ]
Moaddel, Ruin [10 ]
Thomas, Craig J. [9 ]
Zarate, Carlos A., Jr. [11 ]
Pereira, Edna F. R. [5 ]
Gould, Todd D. [1 ,2 ,4 ]
机构
[1] Univ Maryland, Sch Med, Dept Psychiat, Rm 936 MSTF,685 W Baltimore St, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Div Translat Toxicol, Baltimore, MD 21201 USA
[6] Univ Maryland, Sch Med, Programs Toxicol, Baltimore, MD 21201 USA
[7] Univ Maryland, Sch Med, Programs Neurosci, Baltimore, MD 21201 USA
[8] Univ Maryland, Sch Med, Vet Affairs Maryland Hlth Care Syst, Baltimore, MD 21201 USA
[9] Natl Ctr Adv Translat Sci, Div Preclin Innovat, Intramural Res Program, NIH, Rockville, MD USA
[10] NIA, Biomed Res Ctr, Intramural Res Program, NIH, Baltimore, MD 21224 USA
[11] NIMH, Expt Therapeut & Pathophysiol Branch, Intramural Res Program, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
ENANTIOSELECTIVE CAPILLARY-ELECTROPHORESIS; D-ASPARTATE ANTAGONIST; KETAMINE METABOLITE; ANTIDEPRESSANT ACTIONS; MAJOR METABOLITES; IN-VITRO; RECEPTOR; RAT; MECHANISMS; NEURONS;
D O I
10.1124/pharmrev.120.000149
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hydroxynorketamines (HNKs) are formed in vivo after (R,S)-ketamine (ketamine) administration. The 12 HNK stereoisomers are distinguished by the position of cyclohexyl ring hydroxylation (at the 4, 5, or 6 position) and their unique stereochemistry at two stereocenters. Although HNKs were initially classified as inactive metabolites because of their lack of anesthetic effects, more recent studies have begun to reveal their biologic activities. In particular, (2R,6R)- and (2S6)-HNK exert antidepressant-relevant behavioral and physiologic effects in preclinical models, which led to a rapid increase in studies seeking to clarify the mechanisms by which HNKs exert their pharmacological effects. To date, the majority of HNK research has focused on the actions of (2R,6R)-HNK because of its robust behavioral actions in tests of antidepressant effectiveness and its limited adverse effects. This review describes HNK pharmacokinetics and pharmacodynamics, as well as the putative cellular, molecular, and synaptic mechanisms thought to underlie their behavioral effects, both following their metabolism from ketamine and after direct administration in preclinical studies. Converging preclinical evidence indicates that HNKs modulate glutamatergic neurotransmission and downstream signaling pathways in several brain regions, including the hippocampus and prefrontal cortex. Effects on other neurotransmitter systems, as well aspossible effects onneurotrophic andinflammatory processes, and energy metabolism, are also discussed. Additionally, the behavioral effects of HNKs and possible therapeutic applications are described, including the treatment of unipolar and bipolar depression, posttraumatic stress disorder, chronic pain, neuroinflammation, and other anti-inflammatory and analgesic uses. Significance Statement-Preclinical studies indicate that hydroxynorketamines (HNKs) exert antidepressant-relevant behavioral actions and may also have analgesic, anti-inflammatory, and other physiological effects that are relevant for the treatment of a variety of human diseases. This review details the pharmacokinetics and pharmacodynamics of the HNKs, as well as their behavioral actions, putative mechanisms of action, and potential therapeutic applications.
引用
收藏
页码:763 / 791
页数:29
相关论文
共 124 条
[1]   Hydroxynorketamine Blocks N-Methyl-D-Aspartate Receptor Currents by Binding to Closed Receptors [J].
Abbott, Jamie A. ;
Popescu, Gabriela K. .
MOLECULAR PHARMACOLOGY, 2020, 98 (03) :203-210
[2]   (2R,6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline? [J].
Abdallah, Chadi G. .
NEUROPSYCHOPHARMACOLOGY, 2020, 45 (08) :1245-1246
[3]   What's the Buzz About Hydroxynorketamine? Is It the History, the Story, the Debate, or the Promise? [J].
Abdallah, Chadi G. .
BIOLOGICAL PSYCHIATRY, 2017, 81 (08) :E61-E63
[4]   STUDIES ON THE BIOTRANSFORMATION OF KETAMINE .1. IDENTIFICATION OF METABOLITES PRODUCED INVITRO FROM RAT-LIVER MICROSOMAL PREPARATIONS [J].
ADAMS, JD ;
BAILLIE, TA ;
TREVOR, AJ ;
CASTAGNOLI, N .
BIOMEDICAL MASS SPECTROMETRY, 1981, 8 (11) :527-538
[5]   (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism [J].
Ago, Yukio ;
Tanabe, Wataru ;
Higuchi, Momoko ;
Tsukada, Shinji ;
Tanaka, Tatsunori ;
Yamaguchi, Takumi ;
Igarashi, Hisato ;
Yokoyama, Rei ;
Seiriki, Kaoru ;
Kasai, Atsushi ;
Nakazawa, Takanobu ;
Nakagawa, Shinsaku ;
Hashimoto, Kenji ;
Hashimoto, Hitoshi .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2019, 22 (10) :665-674
[6]   Antidepressant actions of ketamine engage cell-specific translation via eIF4E [J].
Aguilar-Valles, Argel ;
De Gregorio, Danilo ;
Matta-Camacho, Edna ;
Eslamizade, Mohammad J. ;
Khlaifia, Abdessattar ;
Skaleka, Agnieszka ;
Lopez-Canul, Martha ;
Torres-Berrio, Angelica ;
Bermudez, Sara ;
Rurak, Gareth M. ;
Simard, Stephanie ;
Salmaso, Natalina ;
Gobbi, Gabriella ;
Lacaille, Jean-Claude ;
Sonenberg, Nahum .
NATURE, 2020, 590 (7845) :315-319
[7]  
Aleksandrova L.R., 2017, Chronic Stress (Thousand Oaks), V1
[8]   Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression [J].
Aleksandrova, Lily R. ;
Wang, Yu Tian ;
Phillips, Anthony G. .
MOLECULAR BRAIN, 2020, 13 (01)
[9]   Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response [J].
Aleksandrova, Lily R. ;
Wang, Yu Tian ;
Phillips, Anthony G. .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2019, 105 :1-23
[10]  
Alkondon M, 1999, J NEUROSCI, V19, P2693